In partnership with
Letter from the editor
Secukinumab maintains improvements in psoriasis through 5 years of treatment
Bermekimab - a future treatment for atopic dermatitis?
JAK1/2 inhibitor effective in alopecia areata
Novel anti-IgE drug enables durable urticaria control
Dual IL-17A and IL-17F blocker leads to unprecedented response rates in psoriasis
Thicker AK lesions benefit from laser pretreatment with high channel density
New standardised cantharidin product against molluscum contagiosum efficacious in two phase 3 trials
Increased cancer risk for patients with keloids
Bruton’s tyrosine kinase inhibitor highly effective in pemphigus vulgaris
Serlopitant reduces pruritus associated with psoriasis
New and emerging atopic dermatitis therapies
Food triggers eczema – an imperturbable belief of patients
Psoriasis and Biologics: The Beat Goes On
JAK inhibitors: a new therapeutic tool for dermatologists
JAK inhibitors: a pathogenesis-directed therapy for alopecia areata
Can JAK inhibitors close the current therapeutic gap in AD?
Hair Loss: No Reason for Therapeutic Nihilism
Vitiligo in children
Surgical treatment for selected vitiligo cases
JAK-inhibitors: an emerging treatment option for vitiligo
Oral antibiotics for acne treatment
Should we use more hormonal therapy?
Plaque psoriasis – Efficacy of guselkumab
Pemphigus patients prone to osteoporosis
Tralokinumab improves eczema and reduces staphylococcus aureus colonisation in AD
Intralesional 5-fluorouracil induced high clearance rates in cutaneous squamous cell carcinoma
Top image: © Zoranm
The content and interpretation of these conference highlights are the views and comments of the speakers/ authors.
BACK TO TOP